Amicus Therapeutics (FOLD) 11.97 $FOLD
Genzyme starts mid-stage trial of oral Fabry disease therapy
Seeking Alpha - at Seeking Alpha - Tue Apr 21, 10:34AM CDT
SHPG: 253.58 (+3.70), PLX: 2.08 (+0.02), SNY: 51.59 (+0.03), FOLD: 11.97 (-0.35)
Amicus Therapeutics Has Returned 37.5% Since SmarTrend Recommendation (FOLD)
Comtex SmarTrend(R) - Tue Apr 21, 9:50AM CDT
SmarTrend identified an Uptrend for Amicus Therapeutics (NASDAQ:FOLD) on February 23rd, 2015 at $8.78. In approximately 2 months, Amicus Therapeutics has returned 37.47% as of today's recent price of $12.07.
FOLD: 11.97 (-0.35)
Technical Coverage on Biotech Stocks -- Agenus, Raptor Pharma, KaloBios Pharma, Amicus Therapeutics, and Sarepta Therapeutics
PR Newswire - Fri Apr 17, 7:45AM CDT
Editor Note: For more information about this release, please scroll to bottom.
AGEN: 6.08 (+0.21), KBIO: 0.57 (-0.02), RPTP: 10.56 (-0.17), SRPT: 13.52 (+0.04), FOLD: 11.97 (-0.35)
Uptrend Call Working As Amicus Therapeutics Stock Rises 36.3% (FOLD)
Comtex SmarTrend(R) - Tue Apr 14, 9:18AM CDT
SmarTrend identified an Uptrend for Amicus Therapeutics (NASDAQ:FOLD) on February 23rd, 2015 at $8.78. In approximately 2 months, Amicus Therapeutics has returned 36.33% as of today's recent price of $11.97.
FOLD: 11.97 (-0.35)
Amicus Therapeutics Honors Fabry Disease Awareness Month and International Pompe Day
GlobeNewswire - Thu Apr 09, 6:30AM CDT
Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, will support several activities surrounding Fabry Disease Awareness Month and International Pompe Day. The Fabry community has designated the month of April to honor and recognize those who are affected by the disease and to promote greater awareness of the disease. The goal of the Second International Pompe Day on April 15 is to foster international awareness of Pompe disease.
FOLD: 11.97 (-0.35)
Global Gaucher Disease Market 2015-2019: Key Players Include Actelion Pharmaceuticals, Genzyme, Pfizer & Shire
M2 - Wed Apr 08, 5:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qfkgft/global_gaucher) has announced the addition of the "Global Gaucher Disease Market 2015-2019" report to their offering. The Global Gaucher Disease market to grow at a CAGR of 7.6% over the period 2014-2019 Gaucher disease is a rare, inherited metabolic disorder caused by the deficiency of the enzyme glucocerebrosidase. This in turn causes the accumulation of certain detrimental lipids in the body, especially the glycolipid glucocerebroside. The lipids are accumulated mainly within the macrophages, blood cells, spleen, liver, and bone marrow. Approximately 34 genetic mutations have been identified that leads to Gaucher disease, out of which there are four most prominent mutations that lead to more than half of the Gaucher disease globally. Some people may have no symptoms of this disease, while some experience severe complications. Some of the clinical manifestations of this disease are hepatosplenomegaly, anemia, thrombocytopenia, and skeletal abnormalities. One key trend upcoming in this market is an increase in awareness among regulatory authorities. Regulatory assistance enables drug makers in developing various treatments. The regulatory bodies are also working toward developing guidelines and providing assistance to drug manufacturers to promote research in this area. According to the report, the special provisions offered to drugs for orphan diseases such as Zavesca and Cerezyme is the major contributor to the market. Special incentives in the form of funding, guidance, and market exclusivity offer an attractive opportunity to the vendors for conducting research in this area. Further, the report states that one of the main challenges that the market faces is the limited patient population. Limited availability of treatment groups prolong the time period during which the vendor can recover R&D expenses of the drug. The restricted patient population also hinders effective evaluation of drugs based on clinical trials. To calculate the market size, the report considers revenue from the sales of various drugs used in the therapy of Gaucher disease, which includes: - Enzyme replacement therapy - Substrate reduction therapy Based on the type of molecule used for the treatment of Gaucher disease, the market is categorized into two segments: - Biologics - Small Molecules Based on the route of administration adopted for the treatment of Gaucher disease, the market is categorized into two segments: - Oral - Parenteral Based on the dosage forms of the drugs used to treat the disease, the Global Gaucher Disease market is categorized into two segments: - Solid - Liquid Key Vendors - Actelion Pharmaceuticals - Genzyme - Pfizer - Shire Other Prominent Vendors - Amicus Therapeutics - Belrose Pharma - Bionaturis - Biosidus - ISU Abxis - JCR Pharmaceuticals - LIXTE Biotechnology - Neuraltus Pharmaceuticals - Protalix BioTherapeutics - Teva Pharmaceuticals - UCB - Utrecht Holdings - Zywie For more information visit http://www.researchandmarkets.com/research/qf...al_gaucher
FOLD: 11.97 (-0.35)
25.7% Return Seen to Date on SmarTrend Amicus Therapeutics Call (FOLD)
Comtex SmarTrend(R) - Mon Apr 06, 5:05PM CDT
SmarTrend identified an Uptrend for Amicus Therapeutics (NASDAQ:FOLD) on February 23rd, 2015 at $8.78. In approximately 1 month, Amicus Therapeutics has returned 25.74% as of today's recent price of $11.04.
FOLD: 11.97 (-0.35)
MEI Pharma Is Undervalued By At Least Half And Will Recover, Here Is Why
StockMatusow - at Seeking Alpha - Wed Apr 01, 7:30AM CDT
Written by Scott Matusow Sometimes in biotech, things do not go as expected. In the case of MEI Pharma ( MEIP ) , this was definitely one of those times when the company's cancer drug failed to meet the main goal in a mid-stage study. In...
ACAD: 38.55 (-0.20), FOLD: 11.97 (-0.35), MEIP: 2.08 (-0.16)
Uptrend Call Working As Amicus Therapeutics Stock Rises 25.4% (FOLD)
Comtex SmarTrend(R) - Fri Mar 27, 10:02AM CDT
SmarTrend identified an Uptrend for Amicus Therapeutics (NASDAQ:FOLD) on February 23rd, 2015 at $8.78. In approximately 1 month, Amicus Therapeutics has returned 25.39% as of today's recent price of $11.01.
FOLD: 11.97 (-0.35)
In Case You Missed It, This Tiny Biotech Is Poised for Explosive Growth
Todd Campbell, The Motley Fool - Motley Fool - Tue Mar 24, 6:06AM CDT
Source: Amicus Therapeutics With few competitors vying for market share and typically high drug prices, rare diseases have become increasingly attractive to drug developers like Amicus Therapeutics , an emerging biotech company that is developing...
SHPG: 253.58 (+3.70), SNY: 51.59 (+0.03), FOLD: 11.97 (-0.35)
Amicus Therapeutics Slumps: FOLD Falls 6.8% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 23, 7:50AM CDT
Amicus Therapeutics saw a big move last session, as the company’s shares fell by nearly 7%. This reverses the recent trend for FOLD as the stock is now up around 34%
ACOR: 33.34 (-1.33), FOLD: 11.97 (-0.35)
Amicus to Seek for Migalastat's Approval in the U.S., EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 20, 4:25PM CDT
Amicus Therapeutics, Inc. (FOLD) announced that it recently met with regulatory authorities in Europe and the U.S. in order to discuss the approval pathways for pipeline candidate - oral small molecule pharmacological chaperone migalastat HCl.
ANIP: 69.79 (+1.24), HZNP: 30.96 (+0.10), SNY: 51.59 (+0.03), FOLD: 11.97 (-0.35)
Seeking Alpha's Biotech Weekly: Biogen's Plaque Attack, Amgen Or Gilead?, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 20, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
TRVN: 6.91 (-0.53), MDT: 78.01 (+0.93), CLDX: 28.95 (+1.08), FOMX: 10.94 (-0.02), AMGN: 169.10 (+0.64), AET: 107.95 (-0.41), NKTR: 10.90 (+0.16), CELG: 115.54 (+0.72), HUM: 180.01 (-0.12), CANF: 2.12 (+0.17), ANTM: 152.84 (-0.04), NVO: 56.37 (-0.17), GILD: 104.18 (-1.02), GERN: 4.20 (-0.04), AZN: 73.35 (+0.65), CLLS: 31.30 (-0.91), WCG: 82.65 (-0.33), FOLD: 11.97 (-0.35), REGN: 472.63 (+9.41), CUR: 1.96 (-0.04)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Mar 20, 11:45AM CDT
RALY: 15.39 (-0.17), GMAN: 8.63 (-0.17), VTAE: 14.04 (+0.02), YOKU: 16.42 (-0.21), NVGN: 7.40 (-0.30), ONTX: 2.48 (-0.05), ISNS: 2.74 (+0.01), EAC: 4.36 (-0.17), ONE: 2.73 (+0.08), VTL: 28.21 (+0.59), VGGL: 2.77 (+0.27), CALA: 12.93 (-1.06), ENVI: 1.80 (unch), CTRP: 66.14 (+0.98), VBLT: 4.37 (-0.08), PRTA: 36.96 (+0.36), NXTD: 2.60 (-0.02), OGEN: 0.97 (+0.09), FOLD: 11.97 (-0.35), BGI: 1.32 (unch)
Critical Alerts For Twitter, Ctrip.com, Prothena, Amicus Therapeutics and Ryder Released By InvestorsObserver
PR Newswire - Fri Mar 20, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for TWTR, CTRP, PRTA, FOLD and R.
R: 97.95 (+1.15), CTRP: 66.14 (+0.98), PRTA: 36.96 (+0.36), TWTR: 51.73 (+0.41), FOLD: 11.97 (-0.35)
Amicus spikes on filing plans
at Investor's Business Daily - Thu Mar 19, 6:09PM CDT
Shares of the small biotech company soared 33.3% to 12.46 after it said that it would file for accelerated approval of lead drug candidate migalastat, an oral treatment for Fabry disease, following positive meetings with FDA and EU regulators. Amicus...
FOLD: 11.97 (-0.35)
Amicus Therapeutics Set to Possibly Pullback After Yesterday's Rally of 33.26%
Comtex SmarTrend(R) - Thu Mar 19, 3:56PM CDT
Amicus Therapeutics (NASDAQ:FOLD) traded in a range yesterday that spanned from a low of $11.63 to a high of $13.20. Yesterday, the shares gained 33.3%, which took the trading range above the 3-day high of $9.95 on volume of 21.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
FOLD: 11.97 (-0.35)
Freeport-McMoRan and Guess are big market movers
AP - Thu Mar 19, 3:43PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market:
VTSS: 5.27 (-0.01), RTRX: 24.45 (+0.09), MSCC: 35.98 (-0.16), KTWO: 22.96 (-0.47), FOLD: 11.97 (-0.35), NKTR: 10.90 (+0.16), ADBE: 75.50 (+0.88)
Genzyme starts mid-stage trial of oral Fabry disease therapy
Seeking Alpha - at Seeking Alpha - Tue Apr 21, 10:34AM CDT
SHPG: 253.58 (+3.70), PLX: 2.08 (+0.02), SNY: 51.59 (+0.03), FOLD: 11.97 (-0.35)
Amicus Therapeutics Has Returned 37.5% Since SmarTrend Recommendation (FOLD)
Comtex SmarTrend(R) - Tue Apr 21, 9:50AM CDT
SmarTrend identified an Uptrend for Amicus Therapeutics (NASDAQ:FOLD) on February 23rd, 2015 at $8.78. In approximately 2 months, Amicus Therapeutics has returned 37.47% as of today's recent price of $12.07.
FOLD: 11.97 (-0.35)
Technical Coverage on Biotech Stocks -- Agenus, Raptor Pharma, KaloBios Pharma, Amicus Therapeutics, and Sarepta Therapeutics
PR Newswire - Fri Apr 17, 7:45AM CDT
Editor Note: For more information about this release, please scroll to bottom.
AGEN: 6.08 (+0.21), KBIO: 0.57 (-0.02), RPTP: 10.56 (-0.17), SRPT: 13.52 (+0.04), FOLD: 11.97 (-0.35)
Uptrend Call Working As Amicus Therapeutics Stock Rises 36.3% (FOLD)
Comtex SmarTrend(R) - Tue Apr 14, 9:18AM CDT
SmarTrend identified an Uptrend for Amicus Therapeutics (NASDAQ:FOLD) on February 23rd, 2015 at $8.78. In approximately 2 months, Amicus Therapeutics has returned 36.33% as of today's recent price of $11.97.
FOLD: 11.97 (-0.35)
Amicus Therapeutics Honors Fabry Disease Awareness Month and International Pompe Day
GlobeNewswire - Thu Apr 09, 6:30AM CDT
Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, will support several activities surrounding Fabry Disease Awareness Month and International Pompe Day. The Fabry community has designated the month of April to honor and recognize those who are affected by the disease and to promote greater awareness of the disease. The goal of the Second International Pompe Day on April 15 is to foster international awareness of Pompe disease.
FOLD: 11.97 (-0.35)
Global Gaucher Disease Market 2015-2019: Key Players Include Actelion Pharmaceuticals, Genzyme, Pfizer & Shire
M2 - Wed Apr 08, 5:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qfkgft/global_gaucher) has announced the addition of the "Global Gaucher Disease Market 2015-2019" report to their offering. The Global Gaucher Disease market to grow at a CAGR of 7.6% over the period 2014-2019 Gaucher disease is a rare, inherited metabolic disorder caused by the deficiency of the enzyme glucocerebrosidase. This in turn causes the accumulation of certain detrimental lipids in the body, especially the glycolipid glucocerebroside. The lipids are accumulated mainly within the macrophages, blood cells, spleen, liver, and bone marrow. Approximately 34 genetic mutations have been identified that leads to Gaucher disease, out of which there are four most prominent mutations that lead to more than half of the Gaucher disease globally. Some people may have no symptoms of this disease, while some experience severe complications. Some of the clinical manifestations of this disease are hepatosplenomegaly, anemia, thrombocytopenia, and skeletal abnormalities. One key trend upcoming in this market is an increase in awareness among regulatory authorities. Regulatory assistance enables drug makers in developing various treatments. The regulatory bodies are also working toward developing guidelines and providing assistance to drug manufacturers to promote research in this area. According to the report, the special provisions offered to drugs for orphan diseases such as Zavesca and Cerezyme is the major contributor to the market. Special incentives in the form of funding, guidance, and market exclusivity offer an attractive opportunity to the vendors for conducting research in this area. Further, the report states that one of the main challenges that the market faces is the limited patient population. Limited availability of treatment groups prolong the time period during which the vendor can recover R&D expenses of the drug. The restricted patient population also hinders effective evaluation of drugs based on clinical trials. To calculate the market size, the report considers revenue from the sales of various drugs used in the therapy of Gaucher disease, which includes: - Enzyme replacement therapy - Substrate reduction therapy Based on the type of molecule used for the treatment of Gaucher disease, the market is categorized into two segments: - Biologics - Small Molecules Based on the route of administration adopted for the treatment of Gaucher disease, the market is categorized into two segments: - Oral - Parenteral Based on the dosage forms of the drugs used to treat the disease, the Global Gaucher Disease market is categorized into two segments: - Solid - Liquid Key Vendors - Actelion Pharmaceuticals - Genzyme - Pfizer - Shire Other Prominent Vendors - Amicus Therapeutics - Belrose Pharma - Bionaturis - Biosidus - ISU Abxis - JCR Pharmaceuticals - LIXTE Biotechnology - Neuraltus Pharmaceuticals - Protalix BioTherapeutics - Teva Pharmaceuticals - UCB - Utrecht Holdings - Zywie For more information visit http://www.researchandmarkets.com/research/qf...al_gaucher
FOLD: 11.97 (-0.35)
25.7% Return Seen to Date on SmarTrend Amicus Therapeutics Call (FOLD)
Comtex SmarTrend(R) - Mon Apr 06, 5:05PM CDT
SmarTrend identified an Uptrend for Amicus Therapeutics (NASDAQ:FOLD) on February 23rd, 2015 at $8.78. In approximately 1 month, Amicus Therapeutics has returned 25.74% as of today's recent price of $11.04.
FOLD: 11.97 (-0.35)
MEI Pharma Is Undervalued By At Least Half And Will Recover, Here Is Why
StockMatusow - at Seeking Alpha - Wed Apr 01, 7:30AM CDT
Written by Scott Matusow Sometimes in biotech, things do not go as expected. In the case of MEI Pharma ( MEIP ) , this was definitely one of those times when the company's cancer drug failed to meet the main goal in a mid-stage study. In...
ACAD: 38.55 (-0.20), FOLD: 11.97 (-0.35), MEIP: 2.08 (-0.16)
Uptrend Call Working As Amicus Therapeutics Stock Rises 25.4% (FOLD)
Comtex SmarTrend(R) - Fri Mar 27, 10:02AM CDT
SmarTrend identified an Uptrend for Amicus Therapeutics (NASDAQ:FOLD) on February 23rd, 2015 at $8.78. In approximately 1 month, Amicus Therapeutics has returned 25.39% as of today's recent price of $11.01.
FOLD: 11.97 (-0.35)
In Case You Missed It, This Tiny Biotech Is Poised for Explosive Growth
Todd Campbell, The Motley Fool - Motley Fool - Tue Mar 24, 6:06AM CDT
Source: Amicus Therapeutics With few competitors vying for market share and typically high drug prices, rare diseases have become increasingly attractive to drug developers like Amicus Therapeutics , an emerging biotech company that is developing...
SHPG: 253.58 (+3.70), SNY: 51.59 (+0.03), FOLD: 11.97 (-0.35)
Amicus Therapeutics Slumps: FOLD Falls 6.8% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 23, 7:50AM CDT
Amicus Therapeutics saw a big move last session, as the company’s shares fell by nearly 7%. This reverses the recent trend for FOLD as the stock is now up around 34%
ACOR: 33.34 (-1.33), FOLD: 11.97 (-0.35)
Amicus to Seek for Migalastat's Approval in the U.S., EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 20, 4:25PM CDT
Amicus Therapeutics, Inc. (FOLD) announced that it recently met with regulatory authorities in Europe and the U.S. in order to discuss the approval pathways for pipeline candidate - oral small molecule pharmacological chaperone migalastat HCl.
ANIP: 69.79 (+1.24), HZNP: 30.96 (+0.10), SNY: 51.59 (+0.03), FOLD: 11.97 (-0.35)
Seeking Alpha's Biotech Weekly: Biogen's Plaque Attack, Amgen Or Gilead?, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 20, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
TRVN: 6.91 (-0.53), MDT: 78.01 (+0.93), CLDX: 28.95 (+1.08), FOMX: 10.94 (-0.02), AMGN: 169.10 (+0.64), AET: 107.95 (-0.41), NKTR: 10.90 (+0.16), CELG: 115.54 (+0.72), HUM: 180.01 (-0.12), CANF: 2.12 (+0.17), ANTM: 152.84 (-0.04), NVO: 56.37 (-0.17), GILD: 104.18 (-1.02), GERN: 4.20 (-0.04), AZN: 73.35 (+0.65), CLLS: 31.30 (-0.91), WCG: 82.65 (-0.33), FOLD: 11.97 (-0.35), REGN: 472.63 (+9.41), CUR: 1.96 (-0.04)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Mar 20, 11:45AM CDT
RALY: 15.39 (-0.17), GMAN: 8.63 (-0.17), VTAE: 14.04 (+0.02), YOKU: 16.42 (-0.21), NVGN: 7.40 (-0.30), ONTX: 2.48 (-0.05), ISNS: 2.74 (+0.01), EAC: 4.36 (-0.17), ONE: 2.73 (+0.08), VTL: 28.21 (+0.59), VGGL: 2.77 (+0.27), CALA: 12.93 (-1.06), ENVI: 1.80 (unch), CTRP: 66.14 (+0.98), VBLT: 4.37 (-0.08), PRTA: 36.96 (+0.36), NXTD: 2.60 (-0.02), OGEN: 0.97 (+0.09), FOLD: 11.97 (-0.35), BGI: 1.32 (unch)
Critical Alerts For Twitter, Ctrip.com, Prothena, Amicus Therapeutics and Ryder Released By InvestorsObserver
PR Newswire - Fri Mar 20, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for TWTR, CTRP, PRTA, FOLD and R.
R: 97.95 (+1.15), CTRP: 66.14 (+0.98), PRTA: 36.96 (+0.36), TWTR: 51.73 (+0.41), FOLD: 11.97 (-0.35)
Amicus spikes on filing plans
at Investor's Business Daily - Thu Mar 19, 6:09PM CDT
Shares of the small biotech company soared 33.3% to 12.46 after it said that it would file for accelerated approval of lead drug candidate migalastat, an oral treatment for Fabry disease, following positive meetings with FDA and EU regulators. Amicus...
FOLD: 11.97 (-0.35)
Amicus Therapeutics Set to Possibly Pullback After Yesterday's Rally of 33.26%
Comtex SmarTrend(R) - Thu Mar 19, 3:56PM CDT
Amicus Therapeutics (NASDAQ:FOLD) traded in a range yesterday that spanned from a low of $11.63 to a high of $13.20. Yesterday, the shares gained 33.3%, which took the trading range above the 3-day high of $9.95 on volume of 21.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
FOLD: 11.97 (-0.35)
Freeport-McMoRan and Guess are big market movers
AP - Thu Mar 19, 3:43PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market:
VTSS: 5.27 (-0.01), RTRX: 24.45 (+0.09), MSCC: 35.98 (-0.16), KTWO: 22.96 (-0.47), FOLD: 11.97 (-0.35), NKTR: 10.90 (+0.16), ADBE: 75.50 (+0.88)
